

CITATION REPORT

List of articles citing

Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A

DOI: 10.1016/j.neuro.2005.01.017
NeuroToxicology, 2005, 26, 785-93.

Source: <https://exaly.com/paper-pdf/39329651/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
434	The myriad uses of botulinum toxin. 2005 , 143, 838-9		3
433	The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. 2006 , 7, 529-38		13
432	Trigger Point Dry Needling. 2006 , 14, 70E-87E		114
431	Treatment of fibromyalgia, myofascial pain, and related disorders. 2006 , 17, 491-510, viii		40
430	The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. 2006 , 122, 315-325		116
429	Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. 2006 , 125, 82-8		122
428	Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. 2006 , 125, 286-295		97
427	Squeezing life into botulinum toxin A in migraine: imploding versus exploding pain. 2006 , 125, 206-207		4
426	The structure and mode of action of different botulinum toxins. 2006 , 13 Suppl 4, 1-9		173
425	[Potential antinociceptive mechanisms of botulinum toxin]. 2006 , 20, 381-2, 384-7		6
424	Migraine: emerging treatment options for preventive and acute attack therapy. 2006 , 11, 419-27		20
423	Botulinum toxin type A for the treatment of migraine. 2006 , 7, 1085-95		23
422	Botulinum toxin injection to facilitate rehabilitation of muscle imbalance syndromes in sports medicine. 2007 , 29, 1832-9		10
421	Restoring balance in focal limb dystonia with botulinum toxin. 2007 , 29, 1778-88		7
420	Successful treatment of notalgia paresthetica with botulinum toxin type A. 2007 , 143, 980-2		66
419	Botulinum toxin, Quo Vadis?. 2007 , 69, 718-23		11
418	Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going. 2007 , 4, 379-86		10

417	Therapeutic Uses of Botulinum Toxin. 2007,	2
416	Botulinum toxin type A in chronic migraine. 2007, 7, 463-70	9
415	[Botulinum toxin for postoperative care after limb surgery in cerebral palsy children]. 2007, 93, 674-81	9
414	[Pharmacological treatment of neurogenic detrusor hyperactivity: intradetrusor botulinum toxin A injections]. 2007, 17, 568-75	5
413	Emerging therapies for migraine. 2007, 3, 610-9	45
412	Botulinum Toxin A Treatment for Chronic Pain in Cerebral Palsy Patients. 2007, 44, 398-401	
411	Botulinum toxin use in the lower urinary tract. 2007, 7, 808-17	
410	Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: a pilot study. 2007, 86, 777-83	25
409	Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. 2007, 100, 1075-80	23
408	Current trends in migraine prophylaxis. 2007, 47 Suppl 1, S52-7	52
407	Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. 2008, 48, 194-200	54
406	Hypnic headache successfully treated with botulinum toxin type A. 2007, 27, 1082-4	20
405	The emerging role of botulinum toxin in the treatment of temporomandibular disorders. 2007, 13, 253-60	50
404	Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. 2007, 51, 1119-27	62
403	Basic Pharmacology of Botulinum Toxin in the Lower Urinary Tract. 2007, 19, 109-114	1
402	Botulinum toxin type-A therapy in cluster headache: an open study. 2007, 8, 236-41	43
401	Intravesical strategies to manage the neurogenic bladder. <i>Current Bladder Dysfunction Reports,</i> 2008, 3, 133-139	0.4 1
400	Cranial neuralgias: from physiopathology to pharmacological treatment. 2008, 29 Suppl 1, S69-78	26

399	Future aspects of botulinum neurotoxins. 2008 , 115, 567-73	16
398	Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. 2008 , 64, 274-83	291
397	Botulinum toxin type A treatment of painful focal neuropathies: new evidence for efference of afferents. 2008 , 64, 236-8	2
396	Intradetrusor botulinum toxin injections for overactive bladder. 2008 , 13, 27-28	
395	Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. 2008 , 15, 205-13	39
394	Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. 2008 , 22, 503-9	34
393	Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. 2008 , 180, 742-8	72
392	The role of botulinum toxin type A in the radiation fibrosis syndrome: a preliminary report. 2008 , 89, 417-21	50
391	Role of botulinum toxin in the treatment of cervical dystonia. 2008 , 26 Suppl 1, 43-53	8
390	Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. 2008 , 12, 189-93	21
389	Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. 2008 , 5, 319-28	93
388	The analgesic effect of botulinum-toxin A on postwhiplash neck pain. 2008 , 24, 5-10	25
387	Pelvic Floor Muscle Dysfunction. 2008 , 14, 417-422	17
386	Relief of intractable pruritus after administration of botulinum toxin A (botox): a case report. 2008 , 31, 303-6	11
385	Neurologic uses of botulinum neurotoxin type A. 2007 , 3, 785-98	41
384	Update on trigeminal neuralgia. 2009 , 9, 323-9	36
383	Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. 2009 , 72, 1473-8	212
382	Mechanism of Action of Botulinum Neurotoxin in the Lower Urinary Tract. 2009 , 231-239.e1	1

381	Clinical Application of Botulinum Neurotoxin in the Treatment of Myofascial Pain Syndromes. 2009 , 283-294	
380	Treatment of Oromandibular Dystonia, Bruxism, and Temporomandibular Disorders with Botulinum Toxin. 2009 , 204-213	
379	Central origin of the antinociceptive action of botulinum toxin type A. 2009 , 94, 234-8	103
378	Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. 2009 , 6, 2523-37	86
377	Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. 2009 , 617, 48-53	79
376	Parkin-related disease clinically diagnosed as a pallido-pyramidal syndrome. 2009 , 24, 138-40	9
375	Botulinum toxin treatment of epilepsia partialis continua. 2009 , 24, 141-3	6
374	The first cinematic presentation of a possible rhythmic movement disorder in a Disney film precedes its scientific debut by 60 years. 2009 , 24, 143-4	3
373	Punding in patients on dopamine agonists for restless leg syndrome. 2009 , 24, 140-1	18
372	Action-induced hemifacial spasm and its resolution with botulinum toxin. 2009 , 24, 147-8	4
371	Pseudo-orthostatic and resting leg tremor in a large Spanish family with homozygous truncating parkin mutation. 2009 , 24, 144-7	8
370	Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. 2009 , 24, 149-51	19
369	Overactive bladder symptoms following urethrolisis procedures. <i>Current Bladder Dysfunction Reports</i> , 2009 , 4, 160-167	0.4
368	Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. 2009 , 161, 737-45	49
367	Botulinum neurotoxin-A for treatment of refractory neck pain: a randomized, double-blind study. 2009 , 10, 1012-7	24
366	Development of future indications for BOTOX. 2009 , 54, 668-74	17
365	Intra-articular Botulinum Toxin Type A: a new approach to treat arthritis joint pain. 2009 , 54, 658-67	46
364	Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. 2009 , 141, 60-9	127

363	Pathophysiological basis of migraine prophylaxis. 2009 , 89, 176-92	84
362	A new indication of botulinum toxin: leiomyoma-related pain. 2009 , 60, 325-8	29
361	Linear and whorled nevoid hypermelanosis: dermatoscopic features. 2009 , 60, 328-31	7
360	Botulinum toxin in pain treatment. 2009 , 59, 366-81	29
359	Botulinum toxin type A for upper limb spasticity after stroke. 2009 , 9, 1713-25	8
358	Botulinum Toxin in the Treatment of Chronic Pelvic Pain Syndromes. 2009 , 257-272.e1	
357	THE ROLE OF INTERVENTIONAL THERAPY IN THE TREATMENT OF NEUROPATHIC PAIN. 2009 , 15, 101-133	
356	Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. 2009 , 19, 347-52	13
355	Use of botulinum toxin in musculoskeletal pain and arthritis. 161-174	
354	Botulinum toxin type A and acute drug costs in migraine with triptan overuse. 2010 , 37, 588-94	8
353	Effect of botulinum toxin on pressure pain threshold and EMG power spectrum of masseter muscle during sustained fatiguing contraction. 2010 , 89, 736-43	7
352	New therapeutic developments in chronic migraine. 2010 , 23, 254-8	18
351	Botulinum toxin injection in neurogenic thoracic outlet syndrome: results and experience using a ultrasound-guided approach. 2010 , 39, 973-80	48
350	Current practice and future directions in the prevention and acute management of migraine. 2010 , 9, 285-98	162
349	Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. 2010 , 151, 606-616	53
348	Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. 2010 , 633, 10-4	92
347	Headache prophylaxis with BoNTA: patient characteristics. 2010 , 50, 63-70	13
346	OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. 2010 , 50, 921-36	601

345	Single CT-guided chemodenervation of the anterior scalene muscle with botulinum toxin for neurogenic thoracic outlet syndrome. 2010 , 11, 504-11	33
344	Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. 2010 , 11, 1827-33	117
343	Treatment effects of intradermal botulinum toxin type A injection on alopecia areata. 2010 , 36 Suppl 4, 2175-81	14
342	Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. 2010 , 24, 43-5	8
341	Botulinum toxin for the lower urinary tract. 2010 , 105, 1046-58	21
340	Ultrasonographic guided botulinum toxin type A treatment for plantar fasciitis: an outcome-based investigation for treating pain and gait changes. 2010 , 42, 136-40	54
339	Botulinum neurotoxin for pain management: insights from animal models. 2010 , 2, 2890-913	50
338	OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. 2010 , 30, 793-803	585
337	Interventions for hemiplegic shoulder pain: systematic review of randomised controlled trials. 2010 , 32, 282-91	48
336	Treatment options in trigeminal neuralgia. 2010 , 3, 107-15	103
335	Botulinum neurotoxin in the treatment of headache disorders. 2010 , 97, 217-32	3
334	Botulinumtoxin bei Kopfschmerzen: Ende eines langen Weges?. 2010 , 37, 327-332	0
333	Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. 2010 , 50, 1406-18	148
332	OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. 2010 , 30, 804-14	649
331	Analgesia. 2010 ,	6
330	Re-engineering clostridial neurotoxins for the treatment of chronic pain: current status and future prospects. 2010 , 24, 173-82	17
329	Trigeminal neuralgia and persistent idiopathic facial pain. 2011 , 11, 1619-29	24
328	Treatment of Somatosensory Tinnitus. 2011 , 649-654	

327	Botulinum Toxin in Urology. 2011 ,	4
326	Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. 2011 , 17 Suppl 1, S28-33	95
325	Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. 2011 , 186, 201-7	143
324	Diagnosis and management of somatosensory tinnitus: review article. 2011 , 66, 1089-94	64
323	Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice. 2011 , 112, 228-35	27
322	A pilot trial of onabotulinumtoxinA for the treatment of cervicothoracic myofascial pain. 2011 , 2, 6	3
321	OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. 2011 , 51, 1358-73	179
320	Insights into the mechanism of onabotulinumtoxinA in chronic migraine. 2011 , 51, 1573-7	58
319	Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats. 2011 , 12, 1385-94	34
318	Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. 2011 , 152, 1988-1996	85
317	[Botulinum toxin type A in the prophylactic treatment of chronic migraine]. 2011 , 25, 563-70; quiz 571	8
316	Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. 2011 , 12, 427-33	79
315	Treatment of chronic migraine. 2011 , 15, 64-9	39
314	Updated perspectives on neurogenic thoracic outlet syndrome. 2011 , 15, 14-21	19
313	Erratum to: Updated Perspectives on Neurogenic Thoracic Outlet Syndrome. 2011 , 15, 85-87	
312	Treatment of chronic migraine headache with onabotulinumtoxinA. 2011 , 15, 336-8	8
311	Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity. 2011 , 30, 1497-502	22
310	Botulinum toxin for subacute/chronic neck pain. 2011 , CD008626	23

309	Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). 2011 , 31, 15650-9	114
308	AHHDurumlarda Botulinum Toksini. 2011 , 48, 1-1	
307	Botulinum toxin intramuscular injections for neck pain: a systematic review and metaanalysis. 2011 , 38, 203-14	12
306	The efficacy of botulinum toxin in patients with cervicogenic headache: a placebo-controlled clinical trial. 2012 , 29, 184-7	7
305	Overview of migraine treatment. 2012 , 2, 399-414	1
304	Randomized controlled study of the efficacy of the injection of botulinum toxin type A versus corticosteroids in chronic plantar fasciitis: results at one and six months. 2012 , 26, 594-606	36
303	Botulinum toxin A in prostate disease: a venom from bench to bed-side. 2012 , 9, 85-94	1
302	Is botulinum toxin A effective for the treatment of plantar fasciitis?. 2012 , 28, 527-33	23
301	Painful diabetic polyneuropathy: approach to diagnosis and management. 2012 , 28, 726-43	26
300	Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. 2012 , 8, 35-48	19
299	Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity. 2012 , 4, 29-34	3
298	DonnBs rfontes sur les traitements visB neuropathique. 2012 , 12, 153-156	
297	A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome. 2012 , 13, 1313-6	8
296	OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine. 2012 , 26, 717-23	2
295	Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. 2012 , 12, 100-8	55
294	A review of thoracic outlet syndrome and the possible role of botulinum toxin in the treatment of this syndrome. 2012 , 4, 1223-35	26
293	OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine. 2012 , 72, 825-45	29
292	Chronic migraine--classification, characteristics and treatment. 2012 , 8, 162-71	104

291	The pharmacological management of neuropathic pain. 2012 , 55, 582	4
290	[Botulinum toxin type A for preventive treatment of chronic migraines]. 2012 , 60, 490-5	
289	Abstracts and Citations. 2012 , 52, 173-182	
288	Evidence-based knee injections for the management of arthritis. 2012 , 13, 740-53	110
287	Treatment of Morton neuroma with botulinum toxin A: a pilot study. 2013 , 33, 497-503	25
286	Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. 2013 , 120, 469-76	28
285	[Contribution of botulinum toxin to maxillo-facial surgery]. 2013 , 114, 72-8	
284	Antinociceptive effects of A1 and A2 type botulinum toxins on carrageenan-induced hyperalgesia in rat. 2013 , 64, 12-9	10
283	Refractory trigeminal neuralgia. Non-surgical treatment options. 2013 , 27, 91-6	45
282	SBOTE study: extracorporeal shock wave therapy versus electrical stimulation after botulinum toxin type a injection for post-stroke spasticity-a prospective randomized trial. 2013 , 39, 283-91	46
281	Onabotulinum toxin A for treatment of chronic migraine with medication overuse. 2013 , 34 Suppl 1, S27-8	6
280	[Chronic migraine]. 2013 , 84, 1460-6	1
279	Treatment of lower urinary tract symptoms: agents for intraprostatic injection. 2013 , 47, 83-90	12
278	Hemicrania continua responsive to botulinum toxin type a: a case report. 2013 , 53, 831-3	15
277	Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. 2013 , 120, 291-8	13
276	A closer look to botulinum neurotoxin type A-induced analgesia. 2013 , 71, 134-9	25
275	Involvement of μ opioid receptors in antinociceptive action of botulinum toxin type A. 2013 , 70, 331-7	35
274	The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis. 2013 , 71, 18-24	29

273	Effectiveness of botulinum toxin A in treatment of refractory erythromelalgia. 2013 , 76, 296-8	3
272	Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder. 2013 , 20, 21-7	24
271	Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B. 2013 , 53, 126-136	13
270	Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia?. 2013 , 14, 92	59
269	Botulinum toxin for painful spasms from focal seizures: theoretical considerations and case report. 2013 , 19, 15-6	3
268	The Face of Chronic Migraine Which Has Started to be Clarified. 2013 , 50, S21-S25	5
267	Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. 2013 , 14, 276-86	36
266	OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. 2013 , 29, 305-10	25
265	New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. 2013 , 9, 161-70	38
264	Botulinum toxin for the treatment of myofascial pain syndromes involving the neck and back: a review from a clinical perspective. 2013 , 2013, 381459	17
263	Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study. 2014 , 19, 126-32	17
262	Use of botulinum neurotoxin in neuropathic pain. 216-221	
261	Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. 2014 , 15, 65	96
260	Therapeutic use of botulinum toxin in migraine: mechanisms of action. 2014 , 171, 4177-92	59
259	A critical evaluation of migraine trigger site deactivation surgery. 2014 , 54, 142-52	28
258	Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of "overactive bladder". 2014 , 33 Suppl 3, S6-13	38
257	A new treatment paradigm for trigeminal neuralgia using Botulinum toxin type A. 2014 , 124, 413-7	23
256	Development of onabotulinumtoxinA for chronic migraine. 2014 , 1329, 67-80	37

255	Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial. 2014 , 6, 5133	13
254	Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles. 2014 , 6, 592-607	14
253	Emerging therapies for chronic migraine. 2014 , 18, 408	5
252	Mechanism of action of onabotulinumtoxinA on lower urinary tract dysfunction. 2014 , 26, 1-4	2
251	Acneiform Eruptions in Dermatology. 2014 ,	2
250	Antinociceptive effect of botulinum toxin type A on experimental abdominal pain. 2014 , 745, 190-5	6
249	Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. 2014 , 192, 1743-9	65
248	Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A. 2014 , 33 Suppl 3, S14-20	21
247	Vulvodynia. 2014 , 28, 1000-12	16
246	Therapy for diabetic neuropathy: an overview. 2014 , 126, 317-33	10
245	Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up. 2014 , 15, 43	35
244	Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. 2014 , 35 Suppl 1, 37-9	12
243	The setting of a botulinum toxin treatment service. 2014 , 35 Suppl 1, 49-50	5
242	Myofascial pain syndrome treatments. 2014 , 25, 357-74	81
241	Treatment of notalgia paresthetica with botulinum toxin A: a double-blind randomized controlled trial. 2014 , 70, 1139-41	28
240	Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study. 2014 , 77, 10-5	17
239	Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. 2014 , 155, 1516-1526	42
238	Botulinum toxin A, brain and pain. 2014 , 119-120, 39-59	109

237	Ultrasound-guided botulinum neurotoxin injections for thoracic outlet syndrome. 269-277	1
236	Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design. 2014 , 118, 1326-35	23
235	WITHDRAWN: Botulinum toxin for subacute/chronic neck pain. 2015 , CD008626	
234	O034. Type of pain and onabotulinumtoxin-A in chronic migraine: four years of follow-up. 2015 , 16, A89	0
233	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. 2015 , 17, 1	93
232	Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. 2015 , 4, 589	22
231	Botulinum toxins for the prevention of migraine in adults. 2015 ,	4
230	Neurotoxins: Expanding Uses of Neuromodulators in Medicine--Headache. 2015 , 136, 104S-110S	9
229	Update on the challenges of treating trigeminal neuralgia. 2015 , 11	2
228	Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. 2015 , 7, 3045-56	23
227	The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee Pain. 2015 , 7, 3388-404	4
226	Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders. 2015 , 7, 3818-44	45
225	Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation. 2015 , 7, 2454-80	24
224	Botulinum Toxin for Neuropathic Pain: A Review of the Literature. 2015 , 7, 3127-54	77
223	Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. 2015 , 20, 107-14	79
222	Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. 2015 , 36 Suppl 1, 29-32	16
221	Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. 2015 , 350, 1-6	34
220	Tratamiento con toxina botulílica del fenómeno de Raynaud severo. 2015 , 30, 410-415	2

219	OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. 2015 , 156, 820-824	96
218	Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. 2015 , 36 Suppl 1, 33-5	28
217	Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview. 2015 , 72, 80-7	4
216	The Treatment of Trigeminal Neuralgia. 2015 , 81-97	
215	Botulinum Toxin Treatment of Pain Disorders. 2015 ,	6
214	Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. 2015 , 15, 100	22
213	Botulinum toxin type A as an adjunct in postoperative pain management in dogs undergoing radical mastectomy. 2015 , 177, 391	5
212	Botulinum neurotoxin type A modulates vesicular release of glutamate from satellite glial cells. 2015 , 19, 1900-9	23
211	New intraprostatic injectables and prostatic urethral lift for male LUTS. 2015 , 12, 461-71	15
210	Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. 2015 , 115, 1-17	12
209	Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. 2017 , 9, e112-e117	12
208	Botulinum Toxin A: An Effective Treatment for Linear Immunoglobulin A Bullous Dermatitis Located in the Axillae. 2016 , 96, 122-3	7
207	Fibromyalgia, Myofascial Pain Syndrome, and Related Conditions. 2016 , 1164-1174	
206	Conservative Treatment of Plantar Fasciitis and Posterior Heel Pain: A Review. 2016 , 04,	2
205	Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality. 2016 , 8,	14
204	Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A. 2016 , 11, e0143024	12
203	Effects of Botulinum Toxin Landmark-Guided Intra-articular Injection in Subjects With Knee Osteoarthritis. 2016 , 8, 1127-1135	20
202	Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. 2015 , 17, 48	40

201	OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial. 2016 , 52, 17-26		26
200	The treatment of occipital neuralgia: Review of 111 cases. <i>Neurochirurgie</i> , 2016 , 62, 233-240	1.4	17
199	[Different types of injection in temporomandibular disorders (TMD) treatment]. 2016 , 117, 256-8		2
198	Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. 2016 , 79, 569-78		56
197	Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. 2016 , 37, 1779-1784		18
196	[Minimally invasive treatment of benign prostatic hyperplasia]. 2016 , 55, 1419-1432		1
195	Chronic migraine treatment: from OnabotulinumtoxinA onwards. 2016 , 16, 1217-27		20
194	Botulinum toxin A in the treatment of trigeminal neuralgia. 2016 , 126, 348-53		22
193	Intraoral administration of botulinum toxin for trigeminal neuropathic pain. 2016 , 121, e148-53		16
192	Update on the Pharmacological Treatment of Chronic Migraine. 2016 , 20, 6		25
191	The Bleph and the Brain: The Effect of Upper Eyelid Surgery on Chronic Headaches. 2017 , 33, 178-181		10
190	Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. 2017 , 36, 338-343		3
189	Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls. 2017 , 197, 1487-1495		11
188	Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomandibular joint of rats. 2017 , 129, 52-57		22
187	Botulinum Toxin for Migraine Headaches. 2017 , 65-89		2
186	Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. 2017 , 378, 182-186		13
185	Protective Effect of Botulinum Toxin Type A Against Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice. 2017 , 43 Suppl 3, S312-S321		5
184	Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies. 2017 , 57, 109-125		85

183	Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain?. 2017 , 46, 322-327	12
182	Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment. 2017 , 38, 141-143	6
181	Botulinum Toxin: From Molecule to Medicine. 2017 , 37-51	0
180	Antinociceptive effect of botulinum toxin A involves alterations in AMPA receptor expression and glutamate release in spinal dorsal horn neurons. 2017 , 357, 197-207	19
179	Bilateral analgesic effects of abobotulinumtoxinA (Dysport) following unilateral administration in the rat. 2017 , 21, 927-937	11
178	Achilles tendon compositional and structural properties are altered after unloading by botox. 2017 , 7, 13067	20
177	An update on emerging therapeutic options for the treatment of trigeminal neuralgia. 2017 , 5, 859-863	1
176	Pharmacological treatment of trigeminal neuralgia. 2017 , 17, 1003-1011	21
175	Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting. 2017 , 38, 1779-1789	19
174	Involvement of substance P in the antinociceptive effect of botulinum toxin type A: Evidence from knockout mice. 2017 , 358, 137-145	30
173	A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury. 2017 , 96, e6919	6
172	Intra-articular injection of Botulinum toxin A reduces neurogenic inflammation in CFA-induced arthritic rat model. 2017 , 126, 70-78	17
171	Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical pain. 2017 , 46, 303-316	27
170	Botulinum neurotoxin type A alleviates mechanical hypersensitivity associated with infraorbital nerve constriction injury in rats. 2017 , 637, 96-101	2
169	Toxine botulinique et douleurs neuropathiques. 2017 , 30, 185-191	
168	Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. 2017 , 10, 2319-2329	21
167	Botulinum Toxin in the Field of Dermatology: Novel Indications. 2017 , 9,	20
166	Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. 2018 , 15, 313-323	42

165	Notalgia paresthetica: a review for dermatologists. 2018 , 57, 388-392	15
164	Botulinum toxin and benign prostatic hyperplasia. 2018 , 5, 33-36	3
163	Emerging therapies for neuropathic pain: new molecules or new indications for old treatments?. 2018 , 159, 576-582	29
162	Pain in focal dystonias - A focused review to address an important component of the disease. 2018 , 54, 17-24	19
161	Morton's interdigital neuroma of the foot: A literature review. 2018 , 24, 92-98	39
160	Botulinum Toxin Treatment of Migraine and Other Headaches. 2018 , 145-165	
159	Botulinum toxin to treat pelvic pain. 2018 , 147, 129-133	7
158	Nummular headache: an update and future prospects. 2018 , 18, 9-19	19
157	CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study. 2018 , 58, 78-87	35
156	Treatment of focal dystonia involving multiple muscles with a single injection of botulinum toxin A to 1 muscle: A case report. 2018 , 97, e12785	1
155	Efficacy of Botulinum Toxin Type A in Trigeminal Neuralgia in a South Asian Cohort. 2018 , 9, 100-105	6
154	Botulinum Toxin for the Treatment of Chronic Migraines. 2018 ,	1
153	Inguinodynia: Nonoperative Management. 2018 , 99-108	
152	Surgical Principles in Inguinal Hernia Repair. 2018 ,	0
151	Neuropathic Pain. 144-157	
150	Expression of Pituitary Adenylate Cyclase-activating Peptide, Calcitonin Gene-related Peptide and Headache Targets in the Trigeminal Ganglia of Rats and Humans. 2018 , 393, 319-332	16
149	Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment. 2018 , 38, 991-1000	19
148	Botulinum toxins for the prevention of migraine in adults. 2018 , 6, CD011616	29

147	Effect of intra-articular Botulinum toxin injections on temporo-mandibular joint pain. 2018 , 119, 319-324	6
146	Migraine Surgery. 2018 ,	1
145	Diagnosis and Management of Head and Face Pain. 2018 ,	0
144	Effect of therapeutic exercise on knee osteoarthritis after intra-articular injection of botulinum toxin type A, hyaluronate or saline: A randomized controlled trial. 2018 , 50, 534-541	19
143	Lumbar Sympathetic Block with Botulinum Toxin Type A and Type B for the Complex Regional Pain Syndrome. 2018 , 10,	12
142	Botox for Migraine Headaches and Facial Pain. 2018 , 171-186	1
141	The Effect of Botulinum Neurotoxin Serotype a Heavy Chain on the Growth Related Proteins and Neurite Outgrowth after Spinal Cord Injury in Rats. 2018 , 10,	5
140	Antipruritic Effects of Botulinum Neurotoxins. 2018 , 10,	9
139	The β subunit-containing GABA receptor: A novel drug target for inhibition of trigeminal activation. 2018 , 140, 1-13	14
138	Does myofascial and trigger point treatment reduce pain and analgesic intake in patients undergoing onabotulinumtoxinA injection due to chronic intractable migraine?. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2018 , 54, 1-12	4.4 13
137	Anatomical Look Into OnabotulinumtoxinA Injection for Chronic Migraine Headache. 2018 , 43, 869-874	3
136	Comparison of efficacy of eight treatments for plantar fasciitis: A network meta-analysis. 2018 , 234, 860-870	17
135	OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. 2019 , 69, 237-240	9
134	Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. 2019 , 11,	2
133	Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Possible Pathomechanisms and Practical Issues. 2019 , 11,	2
132	Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?. 2019 , 11,	3
131	Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients. 2019 , 20, 1815-1821	10
130	Surgical intervention for chronic migraine headache: A systematic review. 2019 , 20, 1-18	4

129	OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity. 2019 , 11,	3
128	Emerging therapies in clinical development and new contributions for neuropathic pain. 2019 , 66, 324-334	1
127	Perineural injection of botulinum toxin-A in painful peripheral nerve injury - a case series: pain relief, safety, sensory profile and sample size recommendation. 2019 , 35, 1793-1803	4
126	A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism. 2019 , 226, 667-672	11
125	Recent advances in understanding/managing trigeminal neuralgia. 2019 , 8,	15
124	Prediction of patient's response to OnabotulinumtoxinA treatment for migraine. 2019 , 5, e01043	5
123	Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice. 2019 , 34, 408-417	0
122	Comparison between intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: a randomized controlled trial. 2019 , 33, 1015-1026	18
121	Una mirada desde la medicina física y rehabilitación al dolor miofascial. 2019 , 30, 428-435	0
120	Botulinum toxin blocks mast cells and prevents rosacea like inflammation. 2019 , 93, 58-64	24
119	Improvement in quality of life after botulinum toxin injection for temporomandibular disorder. 2019 , 120, 2-6	15
118	The analgesic effect of intraarticular OnabotulinumtoxinA in a female murine model of collagenase induced chronic degenerative monoarthritis. 2019 , 158, 8-15	3
117	Botulinum toxin in the management of myofascial pain associated with temporomandibular dysfunction. 2019 , 48, 192-200	7
116	Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine. 2019 , 143, 239-250	22
115	Toxina botulínica tipo A en neuralgia postherpética en región craneofacial: reporte de un caso y revisión de la literatura. 2019 , 11, 27-31	
114	Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice. 2019 , 34, 408-417	6
113	Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. 2020 , 35, 568-578	4
112	Sphenopalatine Ganglion Block with Botulinum Neurotoxin for Treating Trigeminal Neuralgia Using CAD/CAM-Derived Injection Guide. 2020 , 34, 135-140	4

111	Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience. 2020 , 60, 430-440		10
110	The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. 2020 , 48, 300060519895868		6
109	Periorbital botulinum toxin A improves photophobia and sensations of dryness in patients without migraine: Case series of four patients. 2020 , 19, 100809		8
108	Toxine botulinique A et douleurs neuropathiques. 2020 , 204, 379-385		
107	Pharmacological options for the treatment of chronic migraine pain. 2020 , 34, 383-407		1
106	Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. 2020 , 21, 741-748		9
105	Guidelines for botulinum neurotoxin injections in piriformis syndrome. 2021 , 34, 1028-1034		7
104	Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. 2020 , 35, 568-578		
103	Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study. <i>Frontiers in Neurology</i> , 2020 , 11, 417	4.1	37
102	Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. 2020 , 127, 935-951		11
101	A Proposal for Botulinum Toxin Type A Injection Into the Temporal Region in Chronic Migraine Headache. 2020 , 12,		5
100	Botulinum toxin in the management of temporomandibular disorders: a systematic review. 2020 , 58, 508-519		15
99	Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. 2020 , 60, 1259-1272		33
98	Botulinum Toxin and Pain. 2021 , 263, 251-264		9
97	Decreased mandibular cortical bone quality after botulinum toxin injections in masticatory muscles in female adults. 2020 , 10, 3623		9
96	Oily sensitive skin: A review of management options. 2020 , 19, 1016-1020		1
95	Neuronal selectivity of botulinum neurotoxins. 2020 , 178, 20-32		7
94	Female Pelvic Surgery. 2020 ,		

93	An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. 2020 , 9, 195-215	11
92	Botulinum Toxin Injection of a Patient with Intractable Acromio-Clavicular Joint Pain due to Distal Clavicular Osteolysis. 2020 , 21, 3730-3732	0
91	Evidence on ankle injections for osteochondral lesions and osteoarthritis: a systematic review and meta-analysis. 2021 , 45, 509-523	12
90	Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia. 2021 , 61, 392-395	1
89	Prophylaxis of Migraine Protocols and Options. 2021 , 51-73	
88	Innovations in the Management of Temporomandibular Joint Disorders. 2021 , 459-474	
87	Incobotulinum toxin type A for treatment of chronic myofascial pain. 2020 , 63, 37-40	3
86	Foot and Ankle Injections in Athletes. 2021 , 19417381211003619	0
85	Thoracic Outlet Syndrome: A Narrative Review. 2021 , 10,	4
84	Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine. 2021 , 13,	1
83	The Mechanisms of Action of Botulinum Toxin Type A in Nociceptive and Neuropathic Pathways in Cancer Pain. 2021 , 28, 2996-3009	1
82	Current use of botulinum neurotoxin in esthetic practice-Clinical guide and review. 2021 , 20, 1648-1654	0
81	Facets of the problem of infiltrative endometriosis: from pathogenesis to effective therapy. 2021 , 23, 117-124	1
80	The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time.. 2022 , 16, 41-49	1
79	Trigeminal neuralgia: updated management. 2021 , 53, 48	
78	Neurocosmetics in Skincare—The Fascinating World of SkinBrain Connection: A Review to Explore Ingredients, Commercial Products for Skin Aging, and Cosmetic Regulation. 2021 , 8, 66	4
77	Therapeutic Effects of Intra-articular Botulinum Neurotoxin Versus Physical Therapy in Knee Osteoarthritis. 2021 , 11, e112789	5
76	Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives.. 2021 , 2, 705276	1

75	Effects of Botulinum Toxin Type A on Pain among Trigeminal Neuralgia, Myofascial Temporomandibular Disorders, and Oromandibular Dystonia. 2021 , 13,	3
74	Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines. 2021 , 13, e13002	3
73	Botulinum toxin for subacute/chronic neck pain.	2
72	Current Pharmacologic Treatment of Lower Urinary Tract Symptoms. 2014 , 121-222	1
71	Current and emerging pharmacologic therapies for pain and challenges which still lay ahead. 2010 , 617, 539-54	2
70	Botulinum Toxin Endoscopic Injection for Pelvic Pain. 2017 , 325-337	1
69	Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. 2011 , 345-74	9
68	BOTULINUM TOXINS FOR THE TREATMENT OF PAIN. 2009 , 489-501	1
67	Emerging therapies in clinical development and new contributions for neuropathic pain. 2019 , 66, 324-334	5
66	Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle. 2015 , 10, e0140439	5
65	Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: a pre-clinical double-blind and placebo-controlled study. 2011 , 69, 56-63	9
64	Factors affecting the therapeutic effect of botulinum toxin A on trigeminal neuralgia: A follow-up retrospective study of 152 patients. 2019 , 18, 3375-3382	3
63	Botulinum toxin type A in the treatment of Raynaud's phenomenon: A three-year follow-up study. 2018 , 5, 224-229	8
62	Botulinum Toxin Type A Injection for Neuropathic Pain in a Patient With a Brain Tumor: A Case Report. 2017 , 41, 1088-1092	3
61	Evaluation and Management of Neurogenic Thoracic Outlet Syndrome with an Overview of Surgical Approaches: A Comprehensive Review. 2021 , 14, 3085-3095	1
60	Use of botulinum toxin type A in rheumatic diseases. 2021 , 15, 108-113	
59	Myofascial Pain Syndrome. 2008 , 529-537	1
58	Botulinum Toxin: An Effective Treatment for Urge Incontinence. 2009 , 257-274	

57 BoNT for Bladder and Pelvic Pain. **2011**, 79-93

56 Botulinum Toxin Injections in Myofascial Pain Disorders. **2011**, 97-110

55 Biology and Mechanism of Action. **2011**, 13-26

54 Migräne. **2012**, 17-348

53 Migräne. **2012**, 145-381

0

52 Fibromyalgia and Myofascial Pain. **2013**, 59-93

51 Reedŕ Syndrome. **2014**, 221-227

50 Case report : Anterior Open bite after injection of Botulinum Toxin on Masseter Muscles. **2013**, 38, 325-331 1

49 Botulinum Neurotoxins as Therapeutics. **2014**, 553-590

48 Clinical Use of Botulinum Neurotoxins: Pain. **2014**, 153-176

47 Analgesic Effects of Botulinum Neurotoxins: Data from Animal Studies. **2015**, 15-25

46 Migraine and Other Primary Headaches. **2015**, 49-67

45 A proposal of injection points of botulinum toxin into temporal region for chronic migraine. **2017**, 33, 1-6

44 Novos procedimentos osteoarticulares: existem benefŕcios no uso local de PRP e toxina botulŕnica?. *Revista Paulista De Reumatologia*, **2017**, 22-28 0.1

43 Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders. **2018**, 55, 330-336 2

42 Botulinum Toxin. **2018**, 149-173

41 Medical Management of Trigeminal Neuralgia. **2018**, 45-69

40 Auf dem Weg zur optimierten Therapie der Trigeminusneuralgie. **2018**, 29, 40-47

39	Medical Management of Trigeminal Neuralgia. 2019 , 591-609		
38	Bruxism: methods of application and results of treatment with botulinum neuroprotein (Relatox). 2019 , 9, 12-20		1
37	Management of Chronic Daily Headache with Focus on Botulinum Toxin Type A. 2020 , 1, 38-42		
36	Botulinum Toxin Therapy for Voiding Dysfunction. 2020 , 255-282		
35	Botulinum toxin treatment of neuropathic pain. 2020 , 18, 34		
34	Botulinum toxin type A: Basic pharmacological profile and therapeutic applications. <i>Arhiv Za Farmaciju</i> , 2020 , 70, 10-19	0.2	
33	Emerging Treatment Options for Migraine. <i>Annals of the Academy of Medicine, Singapore</i> , 2020 , 49, 226-235		1
32	Radiation Fibrosis Syndrome. 2007 , 19-38		1
31	TRIGEMINAL NEURALGIA AND ITS RECENT ADVANCES. 2020 , 1-4		
30	The use of botulinum neurotoxin type A (Botox) for headaches: a case review. <i>Journal of the Canadian Chiropractic Association</i> , 2006 , 50, 263-70	0.6	3
29	Reed's Syndrome: A Case of Multiple Cutaneous and Uterine Leiomyomas. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2011 , 4, 37-42	1.2	15
28	The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. <i>Journal of Research in Medical Sciences</i> , 2014 , 19, 106-11	1.6	32
27	Chronic migraine - new treatment options. <i>Medica</i> , 2014 , 9, 401-4		1
26	Cluster Headache Associated with Secondary Unilateral Blepharospasm: A Case Report and Review of the Literature. <i>Journal of Ophthalmic and Vision Research</i> , 2017 , 12, 225-227	1.2	1
25	Neuromuscular dysfunction, independent of gait dysfunction, modulates trabecular bone homeostasis in mice. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019 , 19, 79-93	1.3	4
24	Uso intra-articular da toxina botulbica. <i>Revista Paulista De Reumatologia</i> , 2015 , 20-25	0.1	
23	Pain Due To Pathologicalspontaneous Bone Fracture: Interest Of Botulinum Toxin. <i>Neurochirurgie</i> , 2021 ,	1.4	
22	Treatment Options for Patellofemoral Arthritis.. <i>Current Reviews in Musculoskeletal Medicine</i> , 2022 , 1	4.6	1

21	Botulinum Toxin for Neurogenic and Non-neurogenic Bladder Pain. <i>Current Bladder Dysfunction Reports</i> , 2022 , 17, 38-47	0.4	
20	New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
19	Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine.. <i>Pediatric Neurology</i> , 2022 , 130, 21-27	2.9	1
18	A systematic review on extracorporeal shock wave therapy and botulinum toxin for spasticity treatment: a comparison on efficacy.. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2022	4.4	1
17	Botulinum Toxin: An Effective Treatment for Urge Incontinence. 2009 , 257-274		
16	Off-Label Use of Botulinum Toxin in DermatologyCurrent State of the Art. <i>Molecules</i> , 2022 , 27, 3143	4.8	1
15	Botulinum toxin for scalp dysesthesia. <i>Journal of Cutaneous and Aesthetic Surgery</i> , 2022 , 15, 95	0.8	
14	Analgesic Effects of Botulinum Neurotoxins: Data from Animal Studies Volunteers. 2022 , 27-48		
13	Botulinum Toxin Treatment in Migraine and Other Headaches. 2022 , 79-108		
12	Evaluation of Recombinant Botulinum Neurotoxin Type A1 Efficacy in Peripheral Inflammatory Pain in Mice. <i>Frontiers in Molecular Neuroscience</i> , 2022 , 15,	6.1	0
11	A preliminary trial of botulinum toxin type A in patients with vestibular migraine: A longitudinal fMRI study. <i>Frontiers in Neurology</i> , 13,	4.1	1
10	Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine. 2022 , 14, 529		3
9	Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine.		0
8	How Does Botulinum Toxin Inhibit Itch?. 2022 , 14, 701		0
7	Intra-Articular Injection of Botulinum Toxin for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. 2023 , 24, 1486		0
6	Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study. 2023 , 15, 76		1
5	Efficacy of Ultrasound-Guided Injection of Botulinum Toxin, Ozone, and Lidocaine in Piriformis Syndrome. 2023 , 11, 95		0
4	Botulinum Neurotoxin Type a Injection Combined with Absorbable Punctal Plug Insertion: An Effective Therapy for Blepharospasm Patients with Dry Eye. 2023 , 12, 877		0

- 3 Botulinum neurotoxin is both poison and medicine: botulinum therapy and iatrogenic botulism. **2023**, 27, 341-359
- 2 What Is the Efficacy of Intra-articular Injections in the Treatment of Ankle Osteoarthritis? A Systematic Review. **2023**, Publish Ahead of Print,
- 1 New botulinum neurotoxin constructs for treatment of chronic pain. **2023**, 6, e202201631